Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

N2OFF, Inc. (NASDAQ: NITO) ('N2OFF” and the 'Company”), a drug discovery company that is also investing in solar energy ...

As of December 31, 2025, NioCorp had a record consolidated cash balance of $307 million. I believe this fundraising success has also significantly strengthened EXIM's confidence in our ability to ...

A new analysis of global pharmacovigilance data indicates that while reports of psychiatric distress are common among users ...

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...

VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a contr ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

Detailed price information for Clean Air Metals Inc (AIR-X) from The Globe and Mail including charting and trades.

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder: New York Monday, January 12, 202 ...